{"url":"https://lda.senate.gov/api/v1/filings/f402f6f8-e5b8-40e8-b052-20f366099d64/","filing_uuid":"f402f6f8-e5b8-40e8-b052-20f366099d64","filing_type":"Q4","filing_type_display":"4th Quarter - Report","filing_year":2022,"filing_period":"fourth_quarter","filing_period_display":"4th Quarter (Oct 1 - Dec 31)","filing_document_url":"https://lda.senate.gov/filings/public/filing/f402f6f8-e5b8-40e8-b052-20f366099d64/print/","filing_document_content_type":"text/html","income":"40000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Amy Jensen Cunniffe","dt_posted":"2023-01-20T17:17:01-05:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"300 New Jersey Ave, NW","registrant_address_2":"Suite 900","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20001","registrant":{"id":401104582,"url":"https://lda.senate.gov/api/v1/registrants/401104582/","house_registrant_id":null,"name":"SPLITOAK STRATEGIES LLC","description":"Health care consulting","address_1":"300 New Jersey Avenue, NW","address_2":"Suite 300","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"SARAH EGGE","contact_telephone":"+1 703-203-7992","dt_updated":"2026-07-30T12:56:37.934245-04:00"},"client":{"id":202099,"url":"https://lda.senate.gov/api/v1/clients/202099/","client_id":87,"name":"CARIS SCIENCE INC","general_description":"Providing precision medicine services to patients battling aggressive cancers.","client_government_entity":false,"client_self_select":null,"state":"TX","state_display":"Texas","country":"US","country_display":"United States of America","ppb_state":"TX","ppb_state_display":"Texas","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2017-09-19"},"lobbying_activities":[{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Continue access to molecular and advanced genomic testing via telehealth; HR 8845, Multi-Cancer Early Detection Screening Coverage Act; HR 2617 Consolidated Appropriations Act of 2023","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":67072,"prefix":null,"prefix_display":null,"first_name":"AMY","nickname":null,"middle_name":null,"last_name":"JENSEN","suffix":null,"suffix_display":null},"covered_position":"Special Assistant to the President for Legislative Affairs; Assistant to the Speaker for Policy; Legislative Assistant; Policy Analyst","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"Ensuring access to advanced genomic testing for cancer; Providing an appropriate regulatory model for advanced genomic cancer testing, The VALID Act HR 4128 and S 2209; Use of real-world evidence in clinical trials and FDA review. White House Cancer Moonshot Initiative; HR 2617 Consolidated Appropriations Act of 2023","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":67072,"prefix":null,"prefix_display":null,"first_name":"AMY","nickname":null,"middle_name":null,"last_name":"JENSEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"The Valid Act and appropriate regulatory structure for advanced molecular and genomic testing, HR 2617 Consolidated Appropriations Act of 2023","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":67072,"prefix":null,"prefix_display":null,"first_name":"AMY","nickname":null,"middle_name":null,"last_name":"JENSEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"Strengthen the patent system for advanced molecular cancer diagnostic tests; S 4734 Patent Eligibility Restoration Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":67072,"prefix":null,"prefix_display":null,"first_name":"AMY","nickname":null,"middle_name":null,"last_name":"JENSEN","suffix":null,"suffix_display":null},"covered_position":"Special Assistant to the Speaker for Policy; Special Assistant to the President for Legislative Affairs; Policy Analyst; Legislative Assistant","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}